Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.
Identifieur interne : 001F04 ( Main/Exploration ); précédent : 001F03; suivant : 001F05Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.
Auteurs : Georgina V. Long [Australie] ; Jean-Jacques Grob [France] ; Paul Nathan [Royaume-Uni] ; Antoni Ribas [États-Unis] ; Caroline Robert [France] ; Dirk Schadendorf [Allemagne] ; Stephen R. Lane [États-Unis] ; Carmen Mak [États-Unis] ; Philippe Legenne [Suisse] ; Keith T. Flaherty [États-Unis] ; Michael A. Davies [États-Unis]Source :
- The Lancet. Oncology [ 1474-5488 ] ; 2016.
Descripteurs français
- KwdFr :
- Essais contrôlés randomisés comme sujet, Femelle, Humains, Imidazoles (administration et posologie), Mutation, Mâle, Mélanome (génétique), Mélanome (mortalité), Mélanome (traitement médicamenteux), Oximes (administration et posologie), Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Protéines proto-oncogènes B-raf (génétique), Pyridones (administration et posologie), Pyrimidinones (administration et posologie), Études rétrospectives, Évolution de la maladie.
- MESH :
- administration et posologie : Imidazoles, Oximes, Pyridones, Pyrimidinones.
- génétique : Mélanome, Protéines proto-oncogènes B-raf.
- mortalité : Mélanome.
- traitement médicamenteux : Mélanome.
- usage thérapeutique : Protocoles de polychimiothérapie antinéoplasique.
- Essais contrôlés randomisés comme sujet, Femelle, Humains, Mutation, Mâle, Études rétrospectives, Évolution de la maladie.
English descriptors
- KwdEn :
- Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Disease Progression, Female, Humans, Imidazoles (administration & dosage), Male, Melanoma (drug therapy), Melanoma (genetics), Melanoma (mortality), Mutation, Oximes (administration & dosage), Proto-Oncogene Proteins B-raf (genetics), Pyridones (administration & dosage), Pyrimidinones (administration & dosage), Randomized Controlled Trials as Topic, Retrospective Studies.
- MESH :
- chemical , administration & dosage : Imidazoles, Oximes, Pyridones, Pyrimidinones.
- drug therapy : Melanoma.
- genetics : Melanoma, Proto-Oncogene Proteins B-raf.
- mortality : Melanoma.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Disease Progression, Female, Humans, Male, Mutation, Randomized Controlled Trials as Topic, Retrospective Studies.
Abstract
Dabrafenib plus trametinib treatment provides significant benefits over BRAF-inhibitor monotherapy in patients with BRAF(V600E)-mutant or BRAF(V600K)-mutant advanced melanoma; however, in many patients the disease progresses, leading to death. With many treatment options available, understanding clinical factors that predict long-term response and survival for treatments is important for optimisation of patient management. We aimed to identify clinical factors associated with long-term response and survival using pooled data from randomised trials of dabrafenib plus trametinib in patients with metastatic BRAF-mutant melanoma.
DOI: 10.1016/S1470-2045(16)30578-2
PubMed: 27864013
Affiliations:
- Allemagne, Australie, France, Royaume-Uni, Suisse, États-Unis
- Bade-Wurtemberg, Californie, District de Karlsruhe, Massachusetts, New Jersey, Nouvelle-Galles du Sud, Texas, Île-de-France
- Heidelberg, Orsay, Sydney
- Université Paris-Sud, Université de Sydney
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001501
- to stream PubMed, to step Curation: 001479
- to stream PubMed, to step Checkpoint: 001479
- to stream Ncbi, to step Merge: 003F02
- to stream Ncbi, to step Curation: 003F02
- to stream Ncbi, to step Checkpoint: 003F02
- to stream Main, to step Merge: 001F03
- to stream Main, to step Curation: 001F04
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.</title><author><name sortKey="Long, Georgina V" sort="Long, Georgina V" uniqKey="Long G" first="Georgina V" last="Long">Georgina V. Long</name><affiliation wicri:level="4"><nlm:affiliation>Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney, Australia. Electronic address: georgina.long@sydney.edu.au.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region><settlement type="city">Sydney</settlement></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Grob, Jean Jacques" sort="Grob, Jean Jacques" uniqKey="Grob J" first="Jean-Jacques" last="Grob">Jean-Jacques Grob</name><affiliation wicri:level="1"><nlm:affiliation>Service de Dermatologie, Centre Hospitalo-Universitaire Timone, Aix Marseille Université, Marseille CEDEX 05, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Dermatologie, Centre Hospitalo-Universitaire Timone, Aix Marseille Université, Marseille CEDEX 05</wicri:regionArea><wicri:noRegion>Marseille CEDEX 05</wicri:noRegion><wicri:noRegion>Marseille CEDEX 05</wicri:noRegion></affiliation></author><author><name sortKey="Nathan, Paul" sort="Nathan, Paul" uniqKey="Nathan P" first="Paul" last="Nathan">Paul Nathan</name><affiliation wicri:level="1"><nlm:affiliation>Mount Vernon Cancer Centre, Northwood, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Mount Vernon Cancer Centre, Northwood</wicri:regionArea><wicri:noRegion>Northwood</wicri:noRegion></affiliation></author><author><name sortKey="Ribas, Antoni" sort="Ribas, Antoni" uniqKey="Ribas A" first="Antoni" last="Ribas">Antoni Ribas</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Hematology/Oncology, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Hematology/Oncology, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Robert, Caroline" sort="Robert, Caroline" uniqKey="Robert C" first="Caroline" last="Robert">Caroline Robert</name><affiliation wicri:level="4"><nlm:affiliation>Gustave Roussy, Département de Médecine Oncologique, Service de Dermatologie et Université Paris-Sud, Faculté de Médecine, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Gustave Roussy, Département de Médecine Oncologique, Service de Dermatologie et Université Paris-Sud, Faculté de Médecine, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><orgName type="university">Université Paris-Sud</orgName><placeName><settlement type="city">Orsay</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Schadendorf, Dirk" sort="Schadendorf, Dirk" uniqKey="Schadendorf D" first="Dirk" last="Schadendorf">Dirk Schadendorf</name><affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology, University Hospital Essen, Essen, Germany; German Cancer Consortium, Heidelberg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology, University Hospital Essen, Essen, Germany; German Cancer Consortium, Heidelberg</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Heidelberg</settlement></placeName></affiliation></author><author><name sortKey="Lane, Stephen R" sort="Lane, Stephen R" uniqKey="Lane S" first="Stephen R" last="Lane">Stephen R. Lane</name><affiliation wicri:level="2"><nlm:affiliation>Biostatistics, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Biostatistics, Novartis Pharmaceuticals Corporation, East Hanover, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Mak, Carmen" sort="Mak, Carmen" uniqKey="Mak C" first="Carmen" last="Mak">Carmen Mak</name><affiliation wicri:level="2"><nlm:affiliation>Biostatistics, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Biostatistics, Novartis Pharmaceuticals Corporation, East Hanover, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Legenne, Philippe" sort="Legenne, Philippe" uniqKey="Legenne P" first="Philippe" last="Legenne">Philippe Legenne</name><affiliation wicri:level="1"><nlm:affiliation>Global Oncology, Novartis Pharma AG, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Global Oncology, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Flaherty, Keith T" sort="Flaherty, Keith T" uniqKey="Flaherty K" first="Keith T" last="Flaherty">Keith T. Flaherty</name><affiliation wicri:level="2"><nlm:affiliation>Developmental Therapeutics and Melanoma Programs, Massachusetts General Hospital Cancer Center, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Developmental Therapeutics and Melanoma Programs, Massachusetts General Hospital Cancer Center, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Davies, Michael A" sort="Davies, Michael A" uniqKey="Davies M" first="Michael A" last="Davies">Michael A. Davies</name><affiliation wicri:level="2"><nlm:affiliation>Melanoma Medical Oncology and Systems Biology, The University of Texas MDAnderson Cancer Center, Houston, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Melanoma Medical Oncology and Systems Biology, The University of Texas MDAnderson Cancer Center, Houston, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27864013</idno><idno type="pmid">27864013</idno><idno type="doi">10.1016/S1470-2045(16)30578-2</idno><idno type="wicri:Area/PubMed/Corpus">001501</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001501</idno><idno type="wicri:Area/PubMed/Curation">001479</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001479</idno><idno type="wicri:Area/PubMed/Checkpoint">001479</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001479</idno><idno type="wicri:Area/Ncbi/Merge">003F02</idno><idno type="wicri:Area/Ncbi/Curation">003F02</idno><idno type="wicri:Area/Ncbi/Checkpoint">003F02</idno><idno type="wicri:Area/Main/Merge">001F03</idno><idno type="wicri:Area/Main/Curation">001F04</idno><idno type="wicri:Area/Main/Exploration">001F04</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.</title><author><name sortKey="Long, Georgina V" sort="Long, Georgina V" uniqKey="Long G" first="Georgina V" last="Long">Georgina V. Long</name><affiliation wicri:level="4"><nlm:affiliation>Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney, Australia. Electronic address: georgina.long@sydney.edu.au.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region><settlement type="city">Sydney</settlement></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Grob, Jean Jacques" sort="Grob, Jean Jacques" uniqKey="Grob J" first="Jean-Jacques" last="Grob">Jean-Jacques Grob</name><affiliation wicri:level="1"><nlm:affiliation>Service de Dermatologie, Centre Hospitalo-Universitaire Timone, Aix Marseille Université, Marseille CEDEX 05, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Dermatologie, Centre Hospitalo-Universitaire Timone, Aix Marseille Université, Marseille CEDEX 05</wicri:regionArea><wicri:noRegion>Marseille CEDEX 05</wicri:noRegion><wicri:noRegion>Marseille CEDEX 05</wicri:noRegion></affiliation></author><author><name sortKey="Nathan, Paul" sort="Nathan, Paul" uniqKey="Nathan P" first="Paul" last="Nathan">Paul Nathan</name><affiliation wicri:level="1"><nlm:affiliation>Mount Vernon Cancer Centre, Northwood, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Mount Vernon Cancer Centre, Northwood</wicri:regionArea><wicri:noRegion>Northwood</wicri:noRegion></affiliation></author><author><name sortKey="Ribas, Antoni" sort="Ribas, Antoni" uniqKey="Ribas A" first="Antoni" last="Ribas">Antoni Ribas</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Hematology/Oncology, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Hematology/Oncology, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Robert, Caroline" sort="Robert, Caroline" uniqKey="Robert C" first="Caroline" last="Robert">Caroline Robert</name><affiliation wicri:level="4"><nlm:affiliation>Gustave Roussy, Département de Médecine Oncologique, Service de Dermatologie et Université Paris-Sud, Faculté de Médecine, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Gustave Roussy, Département de Médecine Oncologique, Service de Dermatologie et Université Paris-Sud, Faculté de Médecine, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><orgName type="university">Université Paris-Sud</orgName><placeName><settlement type="city">Orsay</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Schadendorf, Dirk" sort="Schadendorf, Dirk" uniqKey="Schadendorf D" first="Dirk" last="Schadendorf">Dirk Schadendorf</name><affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology, University Hospital Essen, Essen, Germany; German Cancer Consortium, Heidelberg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology, University Hospital Essen, Essen, Germany; German Cancer Consortium, Heidelberg</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Heidelberg</settlement></placeName></affiliation></author><author><name sortKey="Lane, Stephen R" sort="Lane, Stephen R" uniqKey="Lane S" first="Stephen R" last="Lane">Stephen R. Lane</name><affiliation wicri:level="2"><nlm:affiliation>Biostatistics, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Biostatistics, Novartis Pharmaceuticals Corporation, East Hanover, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Mak, Carmen" sort="Mak, Carmen" uniqKey="Mak C" first="Carmen" last="Mak">Carmen Mak</name><affiliation wicri:level="2"><nlm:affiliation>Biostatistics, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Biostatistics, Novartis Pharmaceuticals Corporation, East Hanover, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Legenne, Philippe" sort="Legenne, Philippe" uniqKey="Legenne P" first="Philippe" last="Legenne">Philippe Legenne</name><affiliation wicri:level="1"><nlm:affiliation>Global Oncology, Novartis Pharma AG, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Global Oncology, Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Flaherty, Keith T" sort="Flaherty, Keith T" uniqKey="Flaherty K" first="Keith T" last="Flaherty">Keith T. Flaherty</name><affiliation wicri:level="2"><nlm:affiliation>Developmental Therapeutics and Melanoma Programs, Massachusetts General Hospital Cancer Center, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Developmental Therapeutics and Melanoma Programs, Massachusetts General Hospital Cancer Center, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Davies, Michael A" sort="Davies, Michael A" uniqKey="Davies M" first="Michael A" last="Davies">Michael A. Davies</name><affiliation wicri:level="2"><nlm:affiliation>Melanoma Medical Oncology and Systems Biology, The University of Texas MDAnderson Cancer Center, Houston, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Melanoma Medical Oncology and Systems Biology, The University of Texas MDAnderson Cancer Center, Houston, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author></analytic><series><title level="j">The Lancet. Oncology</title><idno type="eISSN">1474-5488</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Disease Progression</term><term>Female</term><term>Humans</term><term>Imidazoles (administration & dosage)</term><term>Male</term><term>Melanoma (drug therapy)</term><term>Melanoma (genetics)</term><term>Melanoma (mortality)</term><term>Mutation</term><term>Oximes (administration & dosage)</term><term>Proto-Oncogene Proteins B-raf (genetics)</term><term>Pyridones (administration & dosage)</term><term>Pyrimidinones (administration & dosage)</term><term>Randomized Controlled Trials as Topic</term><term>Retrospective Studies</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Essais contrôlés randomisés comme sujet</term><term>Femelle</term><term>Humains</term><term>Imidazoles (administration et posologie)</term><term>Mutation</term><term>Mâle</term><term>Mélanome (génétique)</term><term>Mélanome (mortalité)</term><term>Mélanome (traitement médicamenteux)</term><term>Oximes (administration et posologie)</term><term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term><term>Protéines proto-oncogènes B-raf (génétique)</term><term>Pyridones (administration et posologie)</term><term>Pyrimidinones (administration et posologie)</term><term>Études rétrospectives</term><term>Évolution de la maladie</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Imidazoles</term><term>Oximes</term><term>Pyridones</term><term>Pyrimidinones</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Imidazoles</term><term>Oximes</term><term>Pyridones</term><term>Pyrimidinones</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Melanoma</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Melanoma</term><term>Proto-Oncogene Proteins B-raf</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Mélanome</term><term>Protéines proto-oncogènes B-raf</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Melanoma</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Mélanome</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Mélanome</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Disease Progression</term><term>Female</term><term>Humans</term><term>Male</term><term>Mutation</term><term>Randomized Controlled Trials as Topic</term><term>Retrospective Studies</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Essais contrôlés randomisés comme sujet</term><term>Femelle</term><term>Humains</term><term>Mutation</term><term>Mâle</term><term>Études rétrospectives</term><term>Évolution de la maladie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Dabrafenib plus trametinib treatment provides significant benefits over BRAF-inhibitor monotherapy in patients with BRAF(V600E)-mutant or BRAF(V600K)-mutant advanced melanoma; however, in many patients the disease progresses, leading to death. With many treatment options available, understanding clinical factors that predict long-term response and survival for treatments is important for optimisation of patient management. We aimed to identify clinical factors associated with long-term response and survival using pooled data from randomised trials of dabrafenib plus trametinib in patients with metastatic BRAF-mutant melanoma.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>France</li><li>Royaume-Uni</li><li>Suisse</li><li>États-Unis</li></country><region><li>Bade-Wurtemberg</li><li>Californie</li><li>District de Karlsruhe</li><li>Massachusetts</li><li>New Jersey</li><li>Nouvelle-Galles du Sud</li><li>Texas</li><li>Île-de-France</li></region><settlement><li>Heidelberg</li><li>Orsay</li><li>Sydney</li></settlement><orgName><li>Université Paris-Sud</li><li>Université de Sydney</li></orgName></list><tree><country name="Australie"><region name="Nouvelle-Galles du Sud"><name sortKey="Long, Georgina V" sort="Long, Georgina V" uniqKey="Long G" first="Georgina V" last="Long">Georgina V. Long</name></region></country><country name="France"><noRegion><name sortKey="Grob, Jean Jacques" sort="Grob, Jean Jacques" uniqKey="Grob J" first="Jean-Jacques" last="Grob">Jean-Jacques Grob</name></noRegion><name sortKey="Robert, Caroline" sort="Robert, Caroline" uniqKey="Robert C" first="Caroline" last="Robert">Caroline Robert</name></country><country name="Royaume-Uni"><noRegion><name sortKey="Nathan, Paul" sort="Nathan, Paul" uniqKey="Nathan P" first="Paul" last="Nathan">Paul Nathan</name></noRegion></country><country name="États-Unis"><region name="Californie"><name sortKey="Ribas, Antoni" sort="Ribas, Antoni" uniqKey="Ribas A" first="Antoni" last="Ribas">Antoni Ribas</name></region><name sortKey="Davies, Michael A" sort="Davies, Michael A" uniqKey="Davies M" first="Michael A" last="Davies">Michael A. Davies</name><name sortKey="Flaherty, Keith T" sort="Flaherty, Keith T" uniqKey="Flaherty K" first="Keith T" last="Flaherty">Keith T. Flaherty</name><name sortKey="Lane, Stephen R" sort="Lane, Stephen R" uniqKey="Lane S" first="Stephen R" last="Lane">Stephen R. Lane</name><name sortKey="Mak, Carmen" sort="Mak, Carmen" uniqKey="Mak C" first="Carmen" last="Mak">Carmen Mak</name></country><country name="Allemagne"><region name="Bade-Wurtemberg"><name sortKey="Schadendorf, Dirk" sort="Schadendorf, Dirk" uniqKey="Schadendorf D" first="Dirk" last="Schadendorf">Dirk Schadendorf</name></region></country><country name="Suisse"><noRegion><name sortKey="Legenne, Philippe" sort="Legenne, Philippe" uniqKey="Legenne P" first="Philippe" last="Legenne">Philippe Legenne</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F04 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001F04 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27864013
|texte= Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27864013" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |